Skip to main content
. 2022 Sep 28;10:937882. doi: 10.3389/fped.2022.937882

TABLE 4.

Adverse events (AE) by feeding group and time period (SAF population).

Formula-fed (n = 105)
Breastfed (n = 86)
0 to ≤4 months >4 to 12 months 0 to 12 months 0 to ≤4 months >4 to 12 months 0 to 12 months
Subjects with at least one AE 10 (9.5%) 97 (92.4%) 97 (92.4%) 10 (11.6%) 67 (77.9%) 67 (77.9%)
Seriousness
No 10 (9.5%) 96 (91.4%) 97 (92.4%) 10 (11.6%) 67 (77.9%) 67 (77.9%)
Yes 0 (0%) 15 (14.3%) 15 (14.3%) 0 (0%) 11 (12.8%) 11 (12.8%)
Relationship to product
Unrelated 9 (8.6%) 80 (76.2%) 80 (76.2%) 10 (11.6%) 67 (77.9%) 67 (77.9%)
Unlikely 1 (1.0%) 13 (12.4%) 13 (12.4%) 0 (0%) 1 (1.2%) 1 (1.2%)
Probable 0 (0%) 33 (31.4%) 33 (31.4%) 0 (0%) 2 (2.3%) 2 (2.3%)
Related 0 (0%) 4 (3.8%) 4 (3.8%) 0 (0%) 0 (0%) 0 (0%)
Severity
Mild 9 (8.6%) 84 (80.0%) 84 (80.0%) 10 (11.6%) 62 (72.1%) 63 (73.3%)
Moderate 1 (1.0%) 46 (43.8%) 46 (43.8%) 1 (1.2%) 25 (29.1%) 25 (29.1%)
Severe 4 (3.8%) 4 (3.8%) 3 (3.5%) 3 (3.5%)
Caused study discontinuation
No 10 (9.5%) 94 (89.5%) 94 (89.5%) 10 (11.6%) 67 (77.9%) 67 (77.9%)
Yes 0 (0%) 8 (7.6%) 8 (7.6%) 0 (0%) 0 (0%) 0 (0%)
Subjects with at least one allergy-related AE* 0 (0%) 17 (16.2%) 17 (16.2%) 2 (2.3%) 14 (16.3%) 16 (18.6%)

*Including milk allergy, cow’s milk intolerance, lactose intolerance, eczema, atopic dermatitis, dry skin, seborrheic dermatitis, dermatitis, urticaria, and skin reaction. Percentages are computed with respect to the number of subjects per feeding group in the Safety Analysis (SAF) population.